A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
Latest Information Update: 02 Feb 2024
At a glance
- Drugs Povorcitinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 02 Feb 2024 Last checked against European Clinical Trials Database record.
- 12 Oct 2023 Results assessing efficacy and safety of povorcitinib in hidradenitis suppurativa ,published in the Journal of the American Academy of Dermatology.
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.